|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
Human T cell immunity against tumour antigens
If you have a question about this talk, please contact Prof. Jim Kaufman.
Host: Peter Goon (firstname.lastname@example.org)
My group studies human T cells and their potential role in therapy of pre-malignant and malignant diseases. Our main focus has been on human papillomaviruses (HPV) that are associated with the development of cervical cancer. We developed techniques to study HPV specific T cells responses for a series of phase I/II trials with a candidate therapeutic vaccine (TA-HPV). We demonstrated that systemic T cell responses against HPV were relatively weak, both in vaccinated and non-vaccinated patients. Nevertheless we could isolate and grow T cell clones from rare populations, that could kill cancer cells in vitro. This suggests a therapeutic potential for HPV specific T cells but new approaches will be required to induce large numbers of efficacious T cells. We are currently defining new T cell targets based on proteins that are abnormally expressed in cancer. These targets may be applicable to a broad range of human cancers, particularly those caused by oncogenic viruses.
This talk is part of the Immunology in Pathology series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsCambridge Next Generation Sequencing Bioinformatics Day Finance & Accounting Seminar Series Statistics of Prof Philip Dawid
Other talksMigration in Science Workshop: 'The development and facilitation of an emotion and memory group programme for the treatment of complex PTSD' Prof Jan Rehwinkel: Nucleic Acid Sensing by Innate Immune Receptors Disease Migration Homotopy theory with C*-categories Periodicity for finite-dimensional selfinjective algebras